Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury.

BACKGROUND MicroRNAs (miRNAs) are endogenous, small noncoding RNAs. Because of their size, abundance, tissue specificity, and relative stability in plasma, miRNAs hold promise as unique accessible biomarkers to monitor tissue injury. METHODS We investigated the use of liver-, muscle- and brain-specific miRNAs as circulating biomarkers of tissue injury. We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke. RESULTS We observed increases in plasma concentrations of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, respectively. miR-122 and miR-133a illustrated specificity for liver and muscle toxicity, respectively, because they were not detectable in the plasma of animals with toxicity to the other organ. This result contrasted with the results for alanine aminotransferase (ALT) and aspartate aminotransferase, which were both increased with either organ toxicity. Furthermore, miR-122 exhibited a diagnostic sensitivity superior to that of ALT when the results were correlated to the liver histopathologic results. The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values. CONCLUSIONS These results demonstrate that tissue-specific miRNAs may serve as diagnostically sensitive plasma biomarkers of tissue injury.

[1]  V. Arolt,et al.  S100B in brain damage and neurodegeneration , 2003, Microscopy research and technique.

[2]  A. Singer,et al.  The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. , 1995, Annals of emergency medicine.

[3]  S. Chandor Tietz Textbook of Clinical Chemistry and Molecular Diagnostics , 2006 .

[4]  Jin-Moo Lee,et al.  Identification of novel brain biomarkers. , 2006, Clinical chemistry.

[5]  M. Pelsers,et al.  Detection of brain injury by fatty acid-binding proteins , 2005, Clinical chemistry and laboratory medicine.

[6]  J. Lott,et al.  Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring , 2000, Clinical chemistry.

[7]  Edward R. Ashwood,et al.  Tietz Textbook of Clinical Chemistry and Molecular Diagnostics , 2005 .

[8]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[9]  V. Ambros,et al.  Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation , 2004, Genome Biology.

[10]  L. Hood,et al.  Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.

[11]  Dawn G Goodman,et al.  Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[12]  H. Zimmerman,et al.  Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure , 1995, Hepatology.

[13]  L. Stead,et al.  Neuron-Specific Enolase as a Marker for Acute Ischemic Stroke: A Systematic Review , 2005, Cerebrovascular Diseases.

[14]  H. Hårdemark,et al.  S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. , 1987, Stroke.

[15]  Yu Liang,et al.  BMC Genomics , 2007 .

[16]  Manfred Herrmann,et al.  Release of Glial Tissue–Specific Proteins After Acute Stroke: A Comparative Analysis of Serum Concentrations of Protein S-100B and Glial Fibrillary Acidic Protein , 2000, Stroke.

[17]  J. Vaage,et al.  Biochemical markers of neurologic injury in cardiac surgery: the rise and fall of S100beta. , 2001, The Journal of thoracic and cardiovascular surgery.

[18]  K. Ishak,et al.  Ticrynafen‐Associated Hepatic Injury: Analysis of 340 Cases , 1984, Hepatology.

[19]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[20]  J. Broderick,et al.  Association of Serial Biochemical Markers With Acute Ischemic Stroke: The National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study , 2006, Stroke.

[21]  J. Lott,et al.  Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. , 2000, Clinical chemistry.

[22]  Brian S. Roberts,et al.  Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. , 2005, RNA.

[23]  Beate Wittbrodt,et al.  Differences in vertebrate microRNA expression , 2006, Proceedings of the National Academy of Sciences.

[24]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.

[25]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[26]  T. Tuschl,et al.  Identification of Tissue-Specific MicroRNAs from Mouse , 2002, Current Biology.